Neoadjuvant FOLFIRINOX and IMRT Concurrent With FDR Gemcitabine in Borderline Resectable Pancreatic Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
International Journal of Radiation Oncology, Biology, Physics
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase II Trial of Neoadjuvant FOLFIRINOX and IMRT Concurrent With FDR-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer
Int. J. Radiat. Oncol. Biol. Phys 2019 Sep 05;[EPub Ahead of Print], NH Tran, V Sahai, KA Griffith, H Nathan, R Kaza, KC Cuneo, J Shi, E Kim, CJ Sonnenday, CS Cho, TS Lawrence, MM ZalupskiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.